BeOne Medicines shares gain about 5.5% after robust Q2 results and new Phase 3 trials announcement

Traders Union
All News
Stocks
BeOne Medicines surges 5.46% today

Highlights

BeOne Medicines posted Q2 2026 revenue of $1.71 billion, up 30% year over year, with GAAP EPS of $2.05.
Growth was driven by a 31% increase in global BRUKINSA sales to $1.2 billion, with $893 million from U.S. markets.
Shares rallied sharply on strong momentum signals, with technicals indicating a high probability of trading between $335.83 and $359.76 over the next week.

Brukinsa sales growth and trial launches strengthen earnings picture

BeOne Medicines reported Q2 2026 revenues of $1.71 billion, a 30% increase year over year, and GAAP diluted earnings per share of $2.05, substantially higher than the previous year. The strong performance was led by a 31% rise in global BRUKINSA sales, which reached $1.2 billion, with $893 million generated in the U.S. The company also announced four new Phase 3 trials for its solid tumor programs, scheduled for the second half of 2026.

Anton Kharitonov, expert at Traders Union, notes that ONC’s sharp rebound rests on favorable earnings but current technical signals suggest lingering risks. He highlights that the MA-50 remains below the MA-200, indicating a still-bearish longer-term trend, despite recent momentum. Kharitonov points out elevated intraday volatility and overbought readings, which raise caution about unsustainable gains. He reminds that supportive news and Phase 3 trial launches may not shield the stock from fast reversals if sentiment shifts. "For me, the setup encourages defensive positioning — I see limited upside with a heightened risk of correction if support at $342.17 breaks."

Viktoras Karapetjanc, expert at Traders Union, sees ONC as delivering a powerful bullish setup after exceeding revenue forecasts and boosting global BRUKINSA sales. He emphasizes the company's aggressive clinical pipeline and solid U.S. performance as key drivers for sustained growth. Karapetjanc believes the bullish structure remains intact as technical momentum aligns with strong fundamentals. "Further growth is likely — the market offers multiple setups as ONC consolidates above major moving averages and unlocks new catalysts for upside."

Jainam Mehta, market strategist, notes ONC maintains a strong technical bias above all moving averages. He observes daily volatility offers tactical trading potential within the projected $335.83–$359.76 range. Mehta cautions that sideways action may dominate unless a confirmed breakout or breakdown emerges. "A potential breakout above $348.98 could attract momentum buyers, but I would watch for reversal setups if overbought signals intensify."

Short-term bullish momentum amid overbought signals and high volatility

ONC is trading above its MA-20 ($318.38), MA-50 ($295.77), and MA-200 ($314.13), confirming a bullish bias across time frames. Immediate resistance is at $348.98, with support at $342.17, though the longer-term trend remains technically bearish as the MA-50 stays below the MA-200. Momentum indicators remain strong, with both MACD and ADX signaling buy and the RSI at 64.48. The CCI and Bull/Bear Power highlight overbought conditions, while daily intraday volatility is elevated at 1.99% as the price holds near session highs.

Earlier, analysts noted that BeOne Medicines maintained mixed momentum, with intraday buyer strength but ongoing longer-term technical uncertainty. With the recent confirmation of a bullish bias across all major moving averages and a strong earnings beat, the prevailing scenario now points to continued upside potential, with $348.98 as a critical resistance level to watch for confirmation of further gains.

Source of Data: ONC Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.